You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Oui Therapeutics, LLC Topic: NIMH
ABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ROCK IMMUNE LLC Topic: 102
Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: AEROSOL DEVICES INC Topic: NIAID
As the current COVID-19 pandemic has demonstrated, aerosolized pathogens such as SARS-CoV-2 can spread explosively if not quickly detected. Early detection of these airborne pathogens can help control out- breaks, particularly within vulnerable populations in densely populated spaces including assisted living facili- ties, places of worship, military installations, hospitals, and prisons. To date, ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: 1910 GENETICS INC. Topic: 105
PROJECT SUMMARY Never in the history of the United States has the unmet medical need to develop novel, non-opioid therapeutics for chronic pain been more urgent than it is today. More than 65 million US adults suffer from chronic pain, resulting in almost $635 billion in annual healthcare costs. Despite their limited efficacy, and potential for addiction, tolerance, and impaired motor performance, ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: 102
Project Summary Electronic BioSciences (EBS) proposes, in collaboration with Distinguished Professor Henry White at the University of Utah, to develop a nanopore-based extracellular vesicle (EV) characterization system capable of high-resolution, single-vesicle, solution-based characterization, sorting, and isolation. EVs are nanometer-scale, cell-derived vesicles that are produced by nearly all m ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: VOX BIOMEDICAL LLC Topic: NIDA
Project Summary This proposed Phase I/Phase II FastTrack STTR project is intended to lead to the demonstration of a breathalyzer instrument capable of detecting and quantitatively measuring drugs (i.e. cannabinoids and opioids) in exhaled breath (EB). Prior work on the detection of these drugs in EB by means of liquid chromatography and mass spectrometry (LC/MS) demonstrated that these compounds c ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: UNIVERSAL STABILIZATION TECHNOLOGIES, INC. Topic: NIAID
SummaryYellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent res ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: PHOTOPHARMICS, INC. Topic: NIDA
PROJECT SUMMARY Opioid use disorder (OUD) is a rising problem in the United States and around the world, with pain and stress being major factors for initial drug seeking and relapse. The mesolimbic dopamine (DA) system originating in the midbrain ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) in the striatum is an important nexus for the rewarding properties of opioids ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Combined Cardiomyopathy, e.g., of Cancer Chemotherapeutics, and Proarrhythmia for Cardiotoxicity Clinical Trials-in-a-Dish (CTiD) with iPSC-Derived CardiomyocytesSBC: VALA SCIENCES, INC. Topic: NHLBI
Cardiotoxicity is a leading cause of drug discovery attrition across all of preclinical and clinical drug discovery. While the FDA and the Comprehensive in vitro Proarrhythmia Assay initiative (CiPA) are focused primarily on predicting proarrhythmic effects, drug attrition due to cardiomyopathy, or primary cardiac cytotoxicity, may be even more prevalent, is typically currently only carried out vi ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: MERU BIOTECHNOLOGIES Topic: 300
Project Summary: Lung cancer is the leading cause of cancer-related deaths in the United States. Low dose chest computed tomography (CT) screening programs that target high-risk individuals can reduce lung cancer-specific mortality by 20% and overall mortality by 6.9%. There is a growing movement to implement this life saving screening into routine practice, with endorsements from the U.S. Prevent ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health